Intensity Therapeutics INTS
NASDAQ INTS
$3.14 -0.14 (-4.14%)
As of: Oct 21, 2026 · 3:44 PM EDT

Intensity Therapeutics (INTS) Change in Account Payables (2022 - 2023)

Updated

Intensity Therapeutics (INTS) recorded Change in Account Payables of -$1.22 million in Q3 2023, compared with $332,963 a year earlier.

Analysis

Intensity Therapeutics (INTS) Change in Account Payables (2022 - 2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change Payables (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn -
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn -
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn -
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn -
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn -
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn -
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn -70.00 Mn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 18.00 Mn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn -
10 Intensity Therapeutics 8.51 Mn -30.26 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2023 -1.22 Mn
Sep 30, 2022 332,963.00
API Access

Intensity Therapeutics Change in Account Payables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=change-in-account-payables&ticker=INTS&period=max&api_key=YOUR_API_KEY